NYSE: GSK
Explore the latest insights on NYSE: GSK and its impact on China’s pharmaceutical industry. Fineline Info & Tech delivers reliable data, news, and intelligence to help you navigate the complexities of NYSE: GSK’s developments with precision and clarity. Stay informed and enhance your decision-making at flcube.com.
Roche Reports 9M 2026 Sales of CHF 46.493 Billion, Up 6% at CER – Ocrevus Leads as Pharmaceuticals Division Drives Growth and Full-Year Guidance Is Confirmed
Roche (SWX: ROP; OTCMKTS: RHHBY) today reported its financial results for the first nine months of 2026. Group sales reached CHF 46.493 billion (~USD 56.3 billion), a 6% increase at…
Empowering Chinese Pharma’s Global Expansion
Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
